Research programme: acute myeloid leukaemia vaccine - Juvaris

Drug Profile

Research programme: acute myeloid leukaemia vaccine - Juvaris

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Juvaris BioTherapeutics
  • Developer Penn State Milton S. Hershey Medical Center
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
  • 28 Sep 2006 Juvaris BioTherapeutics has received an SBIR grant from the National Cancer Institute for the development of a vaccine for Acute myeloid leukaemia
  • 28 Sep 2004 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top